Plasma genotyping for predicting benefit from osimertinib in patients (pts) with advanced NSCLC
G. Oxnard
Plasma genotyping for predicting benefit from osimertinib in patients (pts) with advanced NSCLC
G. Oxnard
NSCLC TARGETED THERAPY AND CIRCULATING BIOMARKERS